Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.

Presa J, Findlow J, Vojicic J, Williams S, Serra L.

Infect Dis Ther. 2019 Sep;8(3):307-333. doi: 10.1007/s40121-019-0254-1. Epub 2019 Jul 25. Review.

2.

Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence.

Findlow J, Knuf M.

Future Microbiol. 2019 May;14:563-580. doi: 10.2217/fmb-2018-0343. Epub 2019 May 16. Review.

PMID:
31091978
3.

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines.

Findlow J, Balmer P, Borrow R.

Hum Vaccin Immunother. 2019 Mar 18:1-10. doi: 10.1080/21645515.2019.1593082. [Epub ahead of print]

PMID:
30883271
4.

Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.

Findlow J, Nuttens C, Kriz P.

Expert Rev Vaccines. 2019 Mar;18(3):225-239. doi: 10.1080/14760584.2019.1578217. Epub 2019 Mar 1. Review.

PMID:
30821535
5.

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland.

Mulhall RM, Bennett D, Cunney R, Borrow R, Lucidarme J, Findlow J, Jolley KA, Bray J, Maiden MCJ, Moschioni M, Serino L, Stella M, Medini D.

mSphere. 2018 Aug 22;3(4). pii: e00196-18. doi: 10.1128/mSphere.00196-18.

6.

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS.

MBio. 2018 Mar 13;9(2). pii: e00036-18. doi: 10.1128/mBio.00036-18.

7.

Haemophilus influenzae type b (Hib) seroprevalence and current epidemiology in England and Wales.

Collins S, Litt D, Almond R, Findlow J, Linley E, Ramsay M, Borrow R, Ladhani S.

J Infect. 2018 Apr;76(4):335-341. doi: 10.1016/j.jinf.2017.12.010. Epub 2017 Dec 28.

PMID:
29289561
8.

Student Veterans Reintegrating From the Military to the University With Traumatic Injuries: How Does Service Use Relate to Health Status?

Elnitsky CA, Blevins C, Findlow JW, Alverio T, Wiese D.

Arch Phys Med Rehabil. 2018 Feb;99(2S):S58-S64. doi: 10.1016/j.apmr.2017.10.008. Epub 2017 Oct 31.

PMID:
29097180
9.

Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?

Lucidarme J, Lekshmi A, Parikh SR, Bray JE, Hill DM, Bratcher HB, Gray SJ, Carr AD, Jolley KA, Findlow J, Campbell H, Ladhani SN, Ramsay ME, Maiden MCJ, Borrow R.

J Infect. 2017 Aug;75(2):95-103. doi: 10.1016/j.jinf.2017.05.015. Epub 2017 Jun 1.

10.

Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative.

Borrow R, Caugant DA, Ceyhan M, Christensen H, Dinleyici EC, Findlow J, Glennie L, Von Gottberg A, Kechrid A, Vázquez Moreno J, Razki A, Smith V, Taha MK, Tali-Maamar H, Zerouali K; Global Meningococcal Initiative (GMI).

J Infect. 2017 Jul;75(1):1-11. doi: 10.1016/j.jinf.2017.04.007. Epub 2017 Apr 25. Review.

11.

Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.

Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, Clark SA, Findlow J, Pizza M, Ramsay ME, Ladhani SN, Borrow R.

Lancet Infect Dis. 2017 Jul;17(7):754-762. doi: 10.1016/S1473-3099(17)30170-6. Epub 2017 Mar 30.

PMID:
28366725
12.

Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?

Findlow J, Borrow R.

Pathog Dis. 2017 Mar 1;75(2). doi: 10.1093/femspd/ftx025. Review.

PMID:
28334397
13.

An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015.

Lucidarme J, Scott KJ, Ure R, Smith A, Lindsay D, Stenmark B, Jacobsson S, Fredlund H, Cameron JC, Smith-Palmer A, McMenamin J, Gray SJ, Campbell H, Ladhani S, Findlow J, Mölling P, Borrow R.

Euro Surveill. 2016 Nov 10;21(45). pii: 30395. doi: 10.2807/1560-7917.ES.2016.21.45.30395.

14.

A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.

Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, Kleinschmidt A, McCarthy M, Wang H, Toneatto D, Borrow R.

Vaccine. 2017 Jan 11;35(3):427-434. doi: 10.1016/j.vaccine.2016.11.071. Epub 2016 Nov 29.

15.

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.

Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, Holt D, Kamiya H, Saha SK, Sidorenko S, Taha MK, Trotter C, Vázquez Moreno JA, von Gottberg A, Sáfadi MA; Global Meningococcal Initiative.

Expert Rev Vaccines. 2017 Apr;16(4):313-328. doi: 10.1080/14760584.2017.1258308. Epub 2016 Nov 22. Review.

PMID:
27820969
16.

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

Basta NE, Mahmoud AA, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, Bai X, Borrow R.

N Engl J Med. 2016 Jul 21;375(3):220-8. doi: 10.1056/NEJMoa1514866.

17.

Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease.

Vázquez JA, Taha MK, Findlow J, Gupta S, Borrow R.

Epidemiol Infect. 2016 Oct;144(14):3052-3057. Epub 2016 Jun 30. Review.

18.

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

Mesher D, Stanford E, White J, Findlow J, Warrington R, Das S, Pebody R, Borrow R, Soldan K.

PLoS One. 2016 Mar 9;11(3):e0150107. doi: 10.1371/journal.pone.0150107. eCollection 2016.

19.

Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.

Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, Findlow J, Ramsay ME, Borrow R.

Emerg Infect Dis. 2016 Feb;22(2):309-11. doi: 10.3201/eid2202.150369.

20.

Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?

Findlow J.

Hum Vaccin Immunother. 2016;12(1):235-8. doi: 10.1080/21645515.2015.1091131. Review.

21.

Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage.

Lucidarme J, Hill DM, Bratcher HB, Gray SJ, du Plessis M, Tsang RS, Vazquez JA, Taha MK, Ceyhan M, Efron AM, Gorla MC, Findlow J, Jolley KA, Maiden MC, Borrow R.

J Infect. 2015 Nov;71(5):544-52. doi: 10.1016/j.jinf.2015.07.007. Epub 2015 Jul 28.

22.

Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.

Ishola DA, Andrews N, Waight P, Yung CF, Southern J, Bai X, Findlow H, Matheson M, England A, Hallis B, Findlow J, Borrow R, Miller E.

Pediatr Infect Dis J. 2015 Aug;34(8):865-74. doi: 10.1097/INF.0000000000000750.

PMID:
26075813
23.

Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.

Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R.

Vaccine. 2015 Jun 26;33(29):3322-30. doi: 10.1016/j.vaccine.2015.05.027. Epub 2015 May 27.

PMID:
26025807
24.

Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.

Findlow J, Findlow H, Frankland S, Holland A, Holme D, Newton E, Southern J, Waight P, Kaczmarski E, Miller E, Borrow R.

J Occup Med Toxicol. 2014 Jul 16;9:26. doi: 10.1186/1745-6673-9-26. eCollection 2014.

25.

Safe laboratory handling of Neisseria meningitidis.

Borrow R, Findlow J, Gray S, Taylor S, Kaczmarski E.

J Infect. 2014 Apr;68(4):305-12. doi: 10.1016/j.jinf.2014.01.003. Epub 2014 Jan 17. Review.

PMID:
24440738
27.

The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis.

Lucidarme J, Findlow J, Chan H, Feavers IM, Gray SJ, Kaczmarski EB, Parkhill J, Bai X, Borrow R, Bayliss CD.

PLoS One. 2013 Sep 30;8(9):e76932. doi: 10.1371/journal.pone.0076932. eCollection 2013.

28.

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D.

Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14.

29.

Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.

Lucidarme J, Gilchrist S, Newbold LS, Gray SJ, Kaczmarski EB, Richardson L, Bennett JS, Maiden MC, Findlow J, Borrow R.

Clin Vaccine Immunol. 2013 Sep;20(9):1360-9. doi: 10.1128/CVI.00090-13. Epub 2013 Jun 26.

30.

Meningococcal group B vaccines.

Findlow J.

Hum Vaccin Immunother. 2013 Jun;9(6):1387-8. doi: 10.4161/hv.24689. Epub 2013 Jun 6. Review.

31.

A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.

Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Mayer LW, Wang X, Macneil JR, York L, Tan CY, Jansen KU, Anderson AS.

Pediatr Infect Dis J. 2013 Oct;32(10):1096-101. doi: 10.1097/INF.0b013e31829aa63b.

PMID:
23694830
32.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

33.

Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Elias J, Findlow J, Borrow R, Tremmel A, Frosch M, Vogel U.

J Occup Med Toxicol. 2013 Mar 4;8(1):4. doi: 10.1186/1745-6673-8-4.

34.

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R.

Lancet Infect Dis. 2013 May;13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9. Epub 2013 Feb 13.

PMID:
23414709
35.

Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009.

Ladhani S, Ramsay M, Flood J, Campbell H, Slack M, Pebody R, Findlow J, Newton E, Wilding M, Warrington R, Crawford H, Min S, Gray K, Martin S, Frankland S, Bokuvha N, Laher G, Borrow R.

Euro Surveill. 2012 Nov 15;17(46). pii: 20313.

36.

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.

Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, Ledroit M, Hong E, Taha MK, Ellie K, Rajam G, Carlone GM, Claus H, Vogel U, Borrow R, Findlow J, Gilchrist S, Stefanelli P, Fazio C, Carannante A, Oksnes J, Fritzsønn E, Klem AM, Caugant DA, Abad R, Vázquez JA, Rappuoli R, Pizza M, Donnelly JJ, Medini D.

Clin Vaccine Immunol. 2012 Oct;19(10):1609-17. Epub 2012 Aug 8.

37.

Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.

Clarke ET, Williams NA, Dull PM, Findlow J, Borrow R, Finn A, Heyderman RS.

Mucosal Immunol. 2013 Mar;6(2):288-96. doi: 10.1038/mi.2012.70. Epub 2012 Jul 18.

PMID:
22806100
38.

Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.

Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME.

Clin Vaccine Immunol. 2012 Aug;19(8):1126-30. doi: 10.1128/CVI.05655-11. Epub 2012 May 30.

39.

Evaluation of haemophilus influenzae type b vaccine for routine immunization in Nepali infants.

Metz JA, Hanieh S, Pradhan R, Joshi A, Shakya D, Shrestha L, Shrestha A, Upadhyay B, Kelly SC, John TM, Maharjan BD, Yu LM, Omar O, Borrow R, Findlow J, Kelly DF, Thorson SM, Adhikari N, Murdoch DR, Pollard AJ.

Pediatr Infect Dis J. 2012 Apr;31(4):e66-72. doi: 10.1097/INF.0b013e31824a9c37.

PMID:
22418662
40.

Correlation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activity.

Wing JB, Smart L, Borrow R, Findlow J, Findlow H, Lees A, Foster RA, Carlring J, Read RC, Heath AW.

PLoS One. 2012;7(2):e31160. doi: 10.1371/journal.pone.0031160. Epub 2012 Feb 8. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/45ca0028-74a1-427d-ba95-3dbd2acc6b80. Foster, Rachel A [added] Carlring, Jennifer [added].

41.

Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom.

Findlow H, Borrow R, Andrews N, Waight P, Sheasby E, Matheson M, England A, Goldblatt D, Ashton L, Findlow J, Miller E.

Pediatr Infect Dis J. 2012 Jun;31(6):616-22. doi: 10.1097/INF.0b013e31824f34e6.

PMID:
22333698
42.

Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.

Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, Ramsay ME, Kaczmarski EB, Borrow R.

Emerg Infect Dis. 2012 Jan;18(1):63-70. doi: 10.3201/eid1801.110901.

43.

Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis.

Martino A, Magagnoli C, De Conciliis G, D'Ascenzi S, Forster MJ, Allen L, Brookes C, Taylor S, Bai X, Findlow J, Feavers IM, Rodger A, Bolgiano B.

Vaccine. 2012 Feb 8;30(7):1330-42. doi: 10.1016/j.vaccine.2011.12.066. Epub 2011 Dec 27.

PMID:
22210226
44.

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles.

Bai X, Findlow J, Borrow R.

Expert Opin Biol Ther. 2011 Jul;11(7):969-85. doi: 10.1517/14712598.2011.585965. Epub 2011 May 26. Review.

PMID:
21615224
45.

Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.

Wing JB, Smart L, Borrow R, Findlow J, Findlow H, Heath AW, Read RC.

Clin Infect Dis. 2011 Jun;52(11):1317-23. doi: 10.1093/cid/cir198.

PMID:
21596673
46.

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein.

Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM.

Clin Vaccine Immunol. 2011 Jun;18(6):1002-14. doi: 10.1128/CVI.00055-11. Epub 2011 Apr 20.

47.

Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis.

Evans CM, Pratt CB, Matheson M, Vaughan TE, Findlow J, Borrow R, Gorringe AR, Read RC.

Clin Infect Dis. 2011 Jan 1;52(1):70-7. doi: 10.1093/cid/ciq065.

PMID:
21148522
48.

Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP.

Lucidarme J, Newbold LS, Findlow J, Gilchrist S, Gray SJ, Carr AD, Hewitt J, Kaczmarski EB, Borrow R.

Clin Vaccine Immunol. 2011 Feb;18(2):194-202. doi: 10.1128/CVI.00401-10. Epub 2010 Dec 1.

49.

Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ.

Clin Infect Dis. 2010 Nov 15;51(10):1127-37. doi: 10.1086/656741. Epub 2010 Oct 18.

PMID:
20954968
50.

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.

Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ.

Pediatr Infect Dis J. 2010 Nov;29(11):e71-9. doi: 10.1097/INF.0b013e3181f59f6d.

PMID:
20844462

Supplemental Content

Loading ...
Support Center